Meet Mindset Pharma, a Leader in the Race to Develop Next-Gen Psychedelic Compounds
CEO of Mindset Pharma, James Lanthier, gives us an overview of his company and the 4 new psychedelics they are creating. He also discusses some big breaking news!
Psychedelic Spotlight Podcast · Global Trac Solutions Inc., Psychedelic Spotlight, The Psychedelic Investor, James Hallifax, James Lanthier, Mindset Pharma
Audio is streamed directly from the publisher (cdn.simplecast.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In today's episode of the Psychedelic Spotlight Podcast, James Hallifax sits down with James Lanthier, CEO of Mindset Pharma. Mindset Pharma is a psychedelic medicines company that is working on next-generation psychedelic compounds that are inspired by psilocybin and DMT/ 5-MEO-DMT. The company plans on creating medicines to be used for both psychedelic therapy, and microdoses. On January 5th, Mindset announced that they have partnered with the Japanese pharmaceuticals company Otsuka, to help them develop several new psychedelic medicines. In this conversation, the two James' discuss all of this and more, getting to the bottom of Mindset's philosophies and business strategy.
You can find Mindset Pharma trading on the Canadian Securities Exchange under the symbol $MSET and on the American OTC market under the symbol $MSSTF.
*To learn more about Mindset Pharma visit their website: MindsetPharma.com
*Subscribe to our newsletter to get the latest industry news: PsychedelicSpotlight.com